Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How the hell are you?
Here I am today with my rubber ducky -
Quite pleased with my Coll returns. Check out our board -
https://investorshub.advfn.com/Collegium-Pharmaceutical-Inc-COLL-30346
Stay well -
FLO
With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy
Aug. 11, 2023 11:20 AM ET
Summary
Collegium Pharmaceutical presents attractive value for investors with a forward earnings multiple of 4.5x and a 30% return on capital deployed.
Q2 earnings indicate potential for momentum and a target price of $33/share in my view.
The stock has shown technical breakouts and market data supports a bullish outlook.
Net-net, reiterate buy.
Excerpts -
....you're buying COLL at just 4.5x forward earnings as I write, otherwise, 3.5x reported forward EBITDA. In spite of this, the company has produced $4 in net asset value for every $1 in market value for its equity holders, superb value-add as discussed already (trades at 4x book value). This tells me that you've got a company whose net assets are valued very highly by the market, but is generating excellent profitability for its current market value. I smell a mispricing.
Net-net, there is sufficient evidence to suggest that COLL can continue compounding its intrinsic valuation to benefit its equity holders. The firm presents with superb economic characteristics that result in it throwing off piles of cash to shareholders, albeit with small incremental capital growth requirements. This is the kind of business I want to be in, especially with projected values of $1.15Bn/$33 per share on my forward estimates, otherwise c.38% potential investment return. This supports a buy rating in my opinion. Reiterate buy.
Read more:
https://seekingalpha.com/article/4627384-with-30-percent-returns-on-capital-deployed-at-4-4x-earnings-collegium-stock-is-a-buy#comments
With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy
Aug. 11, 2023 11:20 AM ET
Summary
Collegium Pharmaceutical presents attractive value for investors with a forward earnings multiple of 4.5x and a 30% return on capital deployed.
Q2 earnings indicate potential for momentum and a target price of $33/share in my view.
The stock has shown technical breakouts and market data supports a bullish outlook.
Net-net, reiterate buy.
Excerpts -
....you're buying COLL at just 4.5x forward earnings as I write, otherwise, 3.5x reported forward EBITDA. In spite of this, the company has produced $4 in net asset value for every $1 in market value for its equity holders, superb value-add as discussed already (trades at 4x book value). This tells me that you've got a company whose net assets are valued very highly by the market, but is generating excellent profitability for its current market value. I smell a mispricing.
Net-net, there is sufficient evidence to suggest that COLL can continue compounding its intrinsic valuation to benefit its equity holders. The firm presents with superb economic characteristics that result in it throwing off piles of cash to shareholders, albeit with small incremental capital growth requirements. This is the kind of business I want to be in, especially with projected values of $1.15Bn/$33 per share on my forward estimates, otherwise c.38% potential investment return. This supports a buy rating in my opinion. Reiterate buy.
Read more:
https://seekingalpha.com/article/4627384-with-30-percent-returns-on-capital-deployed-at-4-4x-earnings-collegium-stock-is-a-buy#comments
Collegium Pharmaceutical, Inc. (COLL) Q2 2023 Earnings Call Transcript
Excerpts:
We believe that our stock continues to be significantly undervalued and we are committed to leveraging our $100 million share repurchase program to opportunistically return cash to our shareholders.
We are actively pursuing differentiated commercial stage assets that we believe have peak sales potential of more than $150 million in exclusivity into the 2030s.
For perspective in our base case long-range plan, net of paying off our Pharmacon loan we will have greater than $1 billion of cash on hand at the end of 2027. We are committed to leveraging our strong financial position to create value for our shareholders.
We believe that there is a meaningful disconnect between our share price and the intrinsic value of the company and we'll be utilizing the Board authorized accelerated share repurchase program to buy back $50 million of our stock to deliver value to our shareholders.
In November, we expect to provide an update on the status of our contract renegotiations, as well as any new wins, we've secured for BELBUCA and Xtampza for 2024.
In September, we look forward to participating as a leading sponsor in PAINWeek, the largest pain conference in the United States. We'll have a large presence and our medical team expects to present 10 posters, supporting our pain franchise.
The next acquisition we do will be a pivot to a new footprint a new infrastructure, to the organization. So it will be a lower synergy deal than what it is that we've done historically.
....we believe that the case can be made that Xtampza ER should eliminate OxyContin utilization. And that's what we're aspirationally trying to do.
Read more:
https://seekingalpha.com/article/4624235-collegium-pharmaceutical-inc-coll-q2-2023-earnings-call-transcript
Collegium Announces $50 Million Accelerated Share Repurchase Program
Mon, August 7, 2023 at 7:30 AM EDT
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023. Upon completion of this ASR, Collegium will have $50 million remaining under the program.
“The accelerated share repurchase program reinforces our confidence in Collegium's core business, financial strength and strategy,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Our organization is well positioned to maximize the value of our differentiated pain portfolio while executing a disciplined capital deployment strategy. We are committed to effectively deploying capital to create value for our shareholders through focused business development, rapid debt paydown and opportunistic share repurchases.”
Under terms of the agreement, Collegium will pay $50 million to Jefferies LLC and will receive an initial delivery of approximately 1.7 million shares, based on the $23.49 closing stock price of Collegium’s common stock on August 4, 2023, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the fourth quarter of 2023. As of June 30, 2023, Collegium had approximately 34.7 million shares outstanding.
https://finance.yahoo.com/news/collegium-announces-50-million-accelerated-113000989.html
Collegium Announces $50 Million Accelerated Share Repurchase Program
Mon, August 7, 2023 at 7:30 AM EDT
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023. Upon completion of this ASR, Collegium will have $50 million remaining under the program.
“The accelerated share repurchase program reinforces our confidence in Collegium's core business, financial strength and strategy,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Our organization is well positioned to maximize the value of our differentiated pain portfolio while executing a disciplined capital deployment strategy. We are committed to effectively deploying capital to create value for our shareholders through focused business development, rapid debt paydown and opportunistic share repurchases.”
Under terms of the agreement, Collegium will pay $50 million to Jefferies LLC and will receive an initial delivery of approximately 1.7 million shares, based on the $23.49 closing stock price of Collegium’s common stock on August 4, 2023, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the fourth quarter of 2023. As of June 30, 2023, Collegium had approximately 34.7 million shares outstanding.
https://finance.yahoo.com/news/collegium-announces-50-million-accelerated-113000989.html
HC Wainwright & Co. Reiterates Collegium Pharmaceutical (COLL) Neutral Recommendation
FINTEL • 2 HOURS AGO
https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-collegium-pharmaceutical-coll-neutral-recommendation
Needham Reiterates Collegium Pharmaceutical (COLL) Buy Recommendation
FINTEL • 2 HOURS AGO
https://www.nasdaq.com/articles/needham-reiterates-collegium-pharmaceutical-coll-buy-recommendation-2
what is your perspective on what the stock is undervalued?
#1 - Pain is the number one reason Americans seek medical help, according to the U.S. Pain Foundation. That means it affects 7% of Americans.
Pain is our built-in alarm system. It makes us aware that something might be going wrong in our body.
Pain is essential for our survival as it makes us do something to protect our body. For example, if you put your hand too close to a hot stove, you feel the sensation of heat.
https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/Living-with-persistent-pain
****Look up - COLL's DETERx - an Abuse-Deterrent, Extended-Release Technology Platform
#2 - Earnings of 1.26. How many small cap BIOS have any earnings?
#3 - Strong balance sheet enabling a buy back of $100M shares - $50M are now accelerated for purchase - beneficial to shareholders. Is ENTA or RVNC doing such??
#4 - Growing BD rapidly - laser focused to purchase another company with assets, etc.of $150M +
Joe - our stock is significantly undervalued
New Slide show -
https://ir.collegiumpharma.com/static-files/9c4d7cfd-22fd-4912-a3e2-ad94b4aa0bb8
Do Options Traders Know Something About Collegium Pharmaceutical (COLL) Stock We Don't? June 22
Excerpts:
Investors in Collegium Pharmaceutical, Inc. COLL need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 15, 2023 $35.00 Call had some of the highest implied volatility of all equity options today.
Clearly, options traders are pricing in a big move for Collegium Pharmaceutical shares....
Given the way analysts feel about Collegium Pharmaceutical right now, this huge implied volatility could mean there’s a trade developing.
https://finance.yahoo.com/news/options-traders-know-something-collegium-123000185.html
What company are they planning to purchace?
New career opportunities - excerpts:
Senior Quality Assurance Specialist[/b
The Sr. Quality Assurance Specialist on the Quality team at Collegium will be responsible for supporting the manufacturing, testing, and disposition of drug products for commercial use, as well as providing support in the management of critical quality systems. This includes oversight of quality records including change controls, executed batch records, deviations and quality assurance representation during commercial launch activities, particularly as they pertain to Collegium’s GMP virtual manufacturing.
RESPONSIBILITIES -
In-depth knowledge and understanding of FDA expectations, specifically as they relate to batch disposition.
https://boards.greenhouse.io/collegiumpharma/jobs/4244371006
Takeaways from the Jeffries' CC today -
1. If COLL does nothing, they'll have over $1B cash by 2027
2. If COLL was not seen as an Opioid Company, they would have been acquired already
3. there is a disconnect between the company's current share price & its equity/worth
"This will be a BANNER YEAR" - quote - JOE C. ad nauseam.......
a banner year....................................
Yes - a BANNER YEAR for the OFFICERS & DIRECTORS, NOT THE SHAREHOLDERS!!!!!
Collegium to Participate in Jefferies Healthcare Conference
June 1, 2023
STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.
Details of the event are as follows:
Fireside Chat Date and Time: Thursday, June 8, 2023, at 12:30 p.m.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-jefferies-healthcare-conference
Stock Analyst Reiterates Buy Rating on Collegium Pharmaceutical with 35 Price Target - May 30
On May 30, 2023, Serge Belanger, a stock analyst at Needham, reiterated his Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) and maintained a $35 price target. This indicates that Belanger believes the stock is undervalued and has the potential to increase in value. This rating and price target were reaffirmed after the company’s Q1 2023 earnings call. Belanger specializes in analyzing the pharmaceutical industry.
https://beststocks.com/stock-analyst-reiterates-buy-rating-on-colleg/
SEC Filing Details
Document Details
Form 144
Filing Date May 30, 2023
Document Date May 30, 2023
Form Description Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Filing Group Other
Company Collegium Pharmaceutical Inc.
https://ir.collegiumpharma.com/node/11431/html
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the
securities to be sold which has not been publicly disclosed.
Joseph Ciaffoni to sell 31+K shares of restricted stock (as previous compensation) - Form 144
https://ir.collegiumpharma.com/static-files/b15d389a-6e60-4a63-95ab-49ff5790b08f
The BIG question is - when will Mr. Ciaffoni et al BUY shares of the company on the open market - particularly this BANNER YEAR??
Collegium: Turning More Constructive, Especially At 4.4x Earnings
May 25, 2023 8:14 AM ETCollegium Pharmaceutical, Inc. (COLL)
Zach Bristow
2.84K Followers
Summary
I am turning more constructive on Collegium following the outlook on its Q1 numbers.
It came in with record product revenues, the perfect complement to the excellent returns on capital invested.
The market expectations for COLL going forward are mispriced in my opinion.
Investment Summary
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) underperformed the last quarter in-line with my neutral rating on the company back in January. Rolling forward 1 period, I am turning more constructive on the company. I am thus recommending an early buy of the stock at ultra-compressed multiples of 4.4x forward earnings for reasons discussed in this report.
There is plenty to like about COLL, its operations are of the healthy type - record Q1 product revenues, strong returns on capital, and plenty of cash flow to throw off to shareholders. One pullback, is that management haven't reinvested persistently back into the business at these rates of return, suggesting there may be a lack of opportunities to do so. Subsequently, it has been difficult for COLL to catch a long-term bid in my opinion over recent years.
Its market valuation has been buoyant in FY'22-'23, as the firm remains diligently profitable, and growing its balance sheet. In my opinion, it comes back to the opportunities to reinvest capital to grow. For now, the undeniable strengths in the company's business, combined with strengthening core product trends, make COLL investment grade at this point in time. I revise my rating on COLL to a buy.Net-net, revise to buy.
Read more:
https://seekingalpha.com/article/4607278-collegium-turning-more-constructive-4-4x-earnings
Collegium: Turning More Constructive, Especially At 4.4x Earnings
May 25, 2023 8:14 AM ETCollegium Pharmaceutical, Inc. (COLL)
Zach Bristow
2.84K Followers
Summary
I am turning more constructive on Collegium following the outlook on its Q1 numbers.
It came in with record product revenues, the perfect complement to the excellent returns on capital invested.
The market expectations for COLL going forward are mispriced in my opinion.
Investment Summary
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) underperformed the last quarter in-line with my neutral rating on the company back in January. Rolling forward 1 period, I am turning more constructive on the company. I am thus recommending an early buy of the stock at ultra-compressed multiples of 4.4x forward earnings for reasons discussed in this report.
There is plenty to like about COLL, its operations are of the healthy type - record Q1 product revenues, strong returns on capital, and plenty of cash flow to throw off to shareholders. One pullback, is that management haven't reinvested persistently back into the business at these rates of return, suggesting there may be a lack of opportunities to do so. Subsequently, it has been difficult for COLL to catch a long-term bid in my opinion over recent years.
Its market valuation has been buoyant in FY'22-'23, as the firm remains diligently profitable, and growing its balance sheet. In my opinion, it comes back to the opportunities to reinvest capital to grow. For now, the undeniable strengths in the company's business, combined with strengthening core product trends, make COLL investment grade at this point in time. I revise my rating on COLL to a buy.Net-net, revise to buy.
Read more:
https://seekingalpha.com/article/4607278-collegium-turning-more-constructive-4-4x-earnings
Pain is most common chronic ailment in US
Karen Weintraub
USA TODAY May 22
Pain is the most common chronic ailment in America by far, a new study finds, and people in pain tend to stay in pain over the course of a year.
The study, published last week in JAMA Network Open, compared the pain scores of more than 10,000 people from 2019 to 2020.
Pain was found to be far more common than other chronic diseases. If 1,000 people were measured for a year, the study said, there would be 52 cases of chronic pain, 45 cases of high blood pressure, 16 cases of depression and seven cases of diabetes.
Volunteers were asked several questions: “In the past 3 months, how often did you have pain? Would you say never, some days, most days, or every day?” and “Over the past 3 months, how often did pain limit your life or work activities? Would you say never, some days, most days, or every day?”
At the start, about 40% reported no pain, about the same percentage reported some pain, and more than 20% reported chronic pain, suffering for at least the past three months.
In some cases, people recovered over the following year, while for others, their pain progressed. Nearly 15% of those with some pain in 2019 reported chronic pain a year later, while 10% of those reporting chronic pain in 2019 no longer had it the following year.
But the more pain someone was in in 2019, the more likely they were to still be suffering a year later and the greater their chances of having pain that limited their life or work activities.
Older people were more likely to report chronic pain than younger ones, and those without a college degree reported more pain than graduates.
Just over half the study volunteers were women, 54% were ages 18 to 49, and the rest were over 50. Just under 30% were college graduates. The group was roughly reflective of the broader population by race and ethnicity, with 2% American Indian or Alaska Native, 6% Asian, 12% Black, 73% white, and 17% identified as Hispanic.
Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.
In some cases, people with chronic pain recovered over the following year, while for others, their pain progressed.
Investors Eye Collegium Pharmaceutical’s Innovative Approach to Pharmaceuticals as Demand for Specialty Drugs Grows
by Yasmim Mendonça May 20, 2023
As the world grows increasingly reliant on pharmaceutical products, companies like Collegium Pharmaceutical, Inc. (NASDAQ: COLL) are in high demand. The specialty pharmaceutical company has caught the eye of institutional investor LPL Financial LLC, which recently increased its holdings in shares of Collegium Pharmaceutical, Inc. by 7%. According to the company’s most recent disclosure with the Securities and Exchange Commission, LPL Financial LLC now owns 151,463 shares of Collegium Pharmaceutical stock worth $3,514,000.
Collegium Pharmaceutical develops and commercializes abuse-deterrent products for chronic pain patients and others affected by various diseases. Its growing portfolio includes Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. This innovative approach to developing pharmaceuticals has helped them to stand out in an industry where cost-cutting measures usually account for drug development.
The market cap of Collegium Pharmaceutical currently stands at $779.54 million with a price-to-earnings ratio of -26.20 and a price-to-earnings-growth ratio of just 0.24 – indicating solid prospects for continued growth. Meanwhile, its beta stands at a modest 0.81 with both quick and current ratios above one – signifying that it has adequate resources to continue growing.
The company’s stock opened at $22.53 on Friday May 19th with a fifty-day simple moving average of $23.39 and a two-hundred-day simple moving average of $24.13; these figures demonstrate stability despite challenges posed by global economic downturns in recent years.
Despite recent volatility in financial markets worldwide caused by political tensions or pandemic fears across multiple global locations including Asia-Pacific region particularly India as well as Europe through new COVID variant outbreaks- investors’ confidence remains high regarding the future success of Collegium Pharmaceutical.
Read more:
https://beststocks.com/investors-eye-collegium-pharmaceuticals-innovativ/
Collegium Pharmaceutical management to meet virtually with Needham.
Virtual Meeting to be held on May 24 hosted by Needham. Hopefully, we'll have the opportunity to listen.
Also, unfortunately, we were NOT able to attend the A/M, in person, & ask questions!
P.S. No career postings for a week now - quite unusual. M or A coming up??
https://boards.greenhouse.io/collegiumpharma
Top Pharmaceutical Stocks for Q2 2023
Aclaris, Collegium, and Intra-Cellular lead the industry in revenue growth
By NOAH BOLTON Published May 18, 2023
Fastest-Growing Pharmaceutical Stocks
These are the top pharmaceutical stocks as ranked by a growth model that scores companies based on a 50/50 weighting of their most recent quarterly YOY percentage revenue growth and their most recent quarterly YOY earnings-per-share (EPS) growth.
Both sales and earnings are critical factors in the success of a company. Therefore, ranking companies by only one growth metric makes a ranking susceptible to the accounting anomalies of that quarter (such as changes in tax law or restructuring costs) that may make one or the other figure unrepresentative of the business in general. Companies with quarterly EPS or revenue growth of more than 1,000% were excluded as outliers.
Fastest-Growing Pharmaceutical Stocks
Price ($) Market Cap ($B) EPS Growth (%) Revenue Growth (%)
Aclaris Therapeutics Inc. (ACRS) 8.95 0.6 N/A (see company description) 417
Collegium Pharmaceutical Inc. (COLL) 22. 0.8 N/A (see company description) 374
Intra-Cellular Therapies Inc. (ITCI) 63.26 6.0 N/A (see company description)
Collegium Pharmaceutical Inc.: This is a pharmaceutical company that specializes in producing therapies for pain management. On May 4, the company released first-quarter earnings with a net loss widening to $17 million from $13 million a year ago. At the same time, it posted revenue growth of 73% from increased sales of Xtampza ER and Belbuca.
Note Collegium doesn't have an EPS growth figure in the table above because it reported a net loss per share in the most recent quarter
https://www.investopedia.com/top-pharmaceutical-stocks-q2-2023-7499241?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call Transcript
https://finance.yahoo.com/news/collegium-pharmaceutical-inc-nasdaq-coll-191546956.html
Collegium Pharmaceutical (NASDAQ:COLL – APRIL 21) - stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They presently have a $35.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 53.24% from the stock’s current price.
https://www.defenseworld.net/2023/04/21/collegium-pharmaceuticals-coll-buy-rating-reiterated-at-needham-company-llc.html
FWIW - Based in Stoughton, MA we are a team of nearly 300 employees and growing.
https://boards.greenhouse.io/collegiumpharma/jobs/4138138006
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023.
Details of the event are as follows:
Fireside Chat Date and Time: Tuesday, April 18, 2023, at 2:15 p.m. ET
The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-22nd-annual-needham-virtual-healthcare
Collegium Pharmaceutical management to meet with Piper Sandler
Meeting to be held in New York on March 30 hosted by Piper Sandler.
Chronic pain patients struggle to get opioid prescriptions filled, even as CDC eases guidelines March 17, 2023
Layman is one of the millions in the U.S. living with chronic pain. Many have struggled to get opioid prescriptions written and filled since 2016 guidelines from the Centers for Disease Control and Prevention inspired laws cracking down on doctor and pharmacy practices. The CDC recently updated those recommendations to try to ease their impact, but doctors, patients, researchers, and advocates say the damage is done.
https://www.cnn.com/2023/03/17/health/opioid-chronic-pain-cdc-guidelines-khn-partner/index.html
This article today should have mentioned COLL's DETERX technology - but, did NOT!
FWIW - Brandywine Global Investment Management LLC Has $5.21 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Brandywine Global Investment Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Rating) by 19.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 325,262 shares of the specialty pharmaceutical company's stock after buying an additional 54,012 shares during the period. Brandywine Global Investment Management LLC owned approximately 0.97% of Collegium Pharmaceutical worth $5,211,000 as of its most recent filing with the SEC.
https://www.marketbeat.com/instant-alerts/nasdaq-coll-sec-filing-2023-03-03/
Q4 2022 Collegium Pharmaceutical Inc Earnings Call Script -
https://finance.yahoo.com/news/q4-2022-collegium-pharmaceutical-inc-135203188.html
COLL slide presentation - 2.23.2023
https://ir.collegiumpharma.com/static-files/3e57e043-794d-47ac-a59e-2a8a7493aae2
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
February 7, 2023
Exccerpts:
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes. Collegium also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $31,500,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions.
The initial conversion rate is 27.3553 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $36.56 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale price of $28.12 per share of Collegium’s common stock on February 7, 2023. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
Read more:
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-pharmaceutical-inc-prices-upsized-2100-million
BlackRock Increases Position in Collegium Pharmaceutical (COLL)
January 30, 2023
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.73MM shares of Collegium Pharmaceutical Inc (COLL). This represents 17.1% of the company.
In their previous filing dated January 28, 2022 they reported 5.63MM shares and 16.30% of the company, an increase in shares of 1.77% and an increase in total ownership of 0.80% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 29.80% Upside
As of January 26, 2023, the average one-year price target for Collegium Pharmaceutical is $36.72. The forecasts range from a low of $33.33 to a high of $42.00. The average price target represents an increase of 29.80% from its latest reported closing price of $28.29.
The projected annual revenue for Collegium Pharmaceutical is $562MM, an increase of 55.28%. The projected annual EPS is $1.58.
https://www.nasdaq.com/articles/blackrock-increases-position-in-collegium-pharmaceutical-coll
INVESTOR PRESENTATION - JANUARY 2023
https://ir.collegiumpharma.com/static-files/845f6cea-2586-4ca0-a109-a9a074fe03de
Collegium Pharmaceutical (COLL) PT Raised to $33 at Truist Securities from $26.
https://www.streetinsider.com/Analyst+PT+Change/Collegium+Pharmaceutical+%28COLL%29+PT+Raised+to+%2433+at+Truist+Securities/21042862.html
That's it??
Collegium Pharmaceutical price target raised to $35 from $34 at Needham
Needham analyst Serge Belanger raised the firm's price target on Collegium Pharmaceutical to $35 from $34 and keeps a Buy rating on the shares. The company's 2023 guidance was above consensus and reflects its strong execution in managing its product portfolio while highlighting the improvements with its Xtampza GTN, the analyst tells investors in a research note.
Flo estimate - $58 PPS - Dec. 31, 2023
Collegium Provides 2023 Financial Guidance
January 4, 2023
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –
– Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million –
– Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million –
– $100 Million Share Repurchase Program Authorized by the Board of Directors –
STOUGHTON, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2023 full-year financial guidance and provided a business update.
“2022 was a pivotal year for Collegium. We achieved the first two phases of our Three Phase Action Agenda, which included integrating BDSI, completing Xtampza® ER contract renegotiations to ensure gross-to-net of less than 65%, and generating momentum across our differentiated and distinctly positioned pain portfolio,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “With these accomplishments, 2023 is set to be a banner year. We are focused on executing Phase 3, Accelerate, building our leadership position in responsible pain management, and deploying capital to maximize shareholder value.”
“Driven by Xtampza ER and Belbuca®, we expect to immediately accelerate revenue growth making 2023 a banner year for Collegium. With our fully synergized cost structure, we expect significant bottom-line expansion, with adjusted EBITDA expected to grow at over four times the rate of adjusted operating expenses,” said Colleen Tupper, Chief Financial Officer of Collegium. “We are committed to deploying capital in a disciplined manner with business development as our highest priority. We plan to continue rapidly paying down debt and opportunistically returning capital to shareholders through our new $100 million share repurchase program.”
Recent Business Highlights
Collegium’s board of directors authorized a new share repurchase program for 2023 to repurchase up to $100 million in common stock
Returned $19.1 million in capital to shareholders in 2022 under the share repurchase program authorized by Collegium’s board of directors in August 2021, including $4.0 million repurchased since November 3, 2022
In December 2022, the Federal Circuit upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca are valid. Collegium expects that, by virtue of the Federal Circuit’s decision, Alvogen will be barred from entering the market with its product until 2032
Completed Xtampza ER contract renegotiations in 2022, maintaining broad access while significantly decreasing rebates; Xtampza ER gross-to-net is expected to be in the range of 61% to 63% in 2023
Financial Guidance for 2023
Product revenues, net are expected in the range of $565.0 million to $580.0 million
Adjusted operating expenses (excluding stock-based compensation) are expected in the range of $135.0 million to $145.0 million
Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $355.0 million to $370.0 million
* Non-GAAP financial measure. Please refer to the “Non-GAAP Financial Measures” section for details regarding these measures.
Collegium Provides 2023 Financial Guidance
January 4, 2023
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –
– Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million –
– Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million –
– $100 Million Share Repurchase Program Authorized by the Board of Directors –
STOUGHTON, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2023 full-year financial guidance and provided a business update.
“2022 was a pivotal year for Collegium. We achieved the first two phases of our Three Phase Action Agenda, which included integrating BDSI, completing Xtampza® ER contract renegotiations to ensure gross-to-net of less than 65%, and generating momentum across our differentiated and distinctly positioned pain portfolio,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “With these accomplishments, 2023 is set to be a banner year. We are focused on executing Phase 3, Accelerate, building our leadership position in responsible pain management, and deploying capital to maximize shareholder value.”
“Driven by Xtampza ER and Belbuca®, we expect to immediately accelerate revenue growth making 2023 a banner year for Collegium. With our fully synergized cost structure, we expect significant bottom-line expansion, with adjusted EBITDA expected to grow at over four times the rate of adjusted operating expenses,” said Colleen Tupper, Chief Financial Officer of Collegium. “We are committed to deploying capital in a disciplined manner with business development as our highest priority. We plan to continue rapidly paying down debt and opportunistically returning capital to shareholders through our new $100 million share repurchase program.”
Recent Business Highlights
Collegium’s board of directors authorized a new share repurchase program for 2023 to repurchase up to $100 million in common stock
Returned $19.1 million in capital to shareholders in 2022 under the share repurchase program authorized by Collegium’s board of directors in August 2021, including $4.0 million repurchased since November 3, 2022
In December 2022, the Federal Circuit upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca are valid. Collegium expects that, by virtue of the Federal Circuit’s decision, Alvogen will be barred from entering the market with its product until 2032
Completed Xtampza ER contract renegotiations in 2022, maintaining broad access while significantly decreasing rebates; Xtampza ER gross-to-net is expected to be in the range of 61% to 63% in 2023
Financial Guidance for 2023
Product revenues, net are expected in the range of $565.0 million to $580.0 million
Adjusted operating expenses (excluding stock-based compensation) are expected in the range of $135.0 million to $145.0 million
Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $355.0 million to $370.0 million
* Non-GAAP financial measure. Please refer to the “Non-GAAP Financial Measures” section for details regarding these measures.
About Collegium Pharmaceutical, Inc.
Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Excellent revamped web site -
https://www.collegiumpharma.com/
Current job openings:
https://boards.greenhouse.io/collegiumpharma
COLL - $14.03 PPS back in May!! Check it out now -
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
December 22, 2022 at 8:00 AM EST
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry
STOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca® are valid.
In addition to upholding the District Court’s judgment regarding the validity of certain claims in the 8,147,866 patent, expiring in 2027 (the “’866 patent”), and 9,901,539 patent, expiring in 2032 (the “’539 Patent”), the Federal Circuit vacated the District Court’s findings of invalidity with respect to certain claims of the ‘866 patent and the 9,655,843 patent (both expiring in 2027) and remanded such claims for reconsideration by the District Court.
Alvogen conceded infringement of all claims at issue in the litigation, and accordingly, Collegium expects that, by virtue of the Federal Circuit’s decision, Alvogen will be barred from entering the market with its product until 2032.
“We are very pleased with the Federal Circuit’s decision, which reinforces the strength of the patents supporting Belbuca, and we look forward to continuing to supply this innovative and differentiated product to appropriate patients,” said Shirley Kuhlmann, General Counsel and Chief Administrative Officer of Collegium.
https://ir.collegiumpharma.com/news-releases/news-release-details/appeals-court-affirms-validity-collegiums-belbucar-patents